advertisement
Molecular Therapy 39
Showing records 1 to 25 | Display all abstracts in Molecular Therapy98807 CRISPR genome surgery in a novel humanized model for autosomal dominant retinitis pigmentosa
Wu WH
Molecular Therapy 2022; 30: 1407-1420
98223 Endosomal disentanglement of a transducible artificial transcription factor targeting endothelin receptor A
Bippes CC
Molecular Therapy 2022; 30: 855-867
98727 NMNAT2 is downregulated in glaucomatous RGCs, and RGC-specific gene therapy rescues neurodegeneration and visual function
Fang F
Molecular Therapy 2022; 30: 1421-1431
98807 CRISPR genome surgery in a novel humanized model for autosomal dominant retinitis pigmentosa
Tsai YT
Molecular Therapy 2022; 30: 1407-1420
98727 NMNAT2 is downregulated in glaucomatous RGCs, and RGC-specific gene therapy rescues neurodegeneration and visual function
Zhuang P
Molecular Therapy 2022; 30: 1421-1431
98223 Endosomal disentanglement of a transducible artificial transcription factor targeting endothelin receptor A
Kohler C
Molecular Therapy 2022; 30: 855-867
98727 NMNAT2 is downregulated in glaucomatous RGCs, and RGC-specific gene therapy rescues neurodegeneration and visual function
Feng X
Molecular Therapy 2022; 30: 1421-1431
98807 CRISPR genome surgery in a novel humanized model for autosomal dominant retinitis pigmentosa
Huang IW
Molecular Therapy 2022; 30: 1407-1420
98223 Endosomal disentanglement of a transducible artificial transcription factor targeting endothelin receptor A
Garcia-Tirado E
Molecular Therapy 2022; 30: 855-867
98807 CRISPR genome surgery in a novel humanized model for autosomal dominant retinitis pigmentosa
Huang IW
Molecular Therapy 2022; 30: 1407-1420
98727 NMNAT2 is downregulated in glaucomatous RGCs, and RGC-specific gene therapy rescues neurodegeneration and visual function
Liu P
Molecular Therapy 2022; 30: 1421-1431
98223 Endosomal disentanglement of a transducible artificial transcription factor targeting endothelin receptor A
Burri R
Molecular Therapy 2022; 30: 855-867
98807 CRISPR genome surgery in a novel humanized model for autosomal dominant retinitis pigmentosa
Cheng CH
Molecular Therapy 2022; 30: 1407-1420
98727 NMNAT2 is downregulated in glaucomatous RGCs, and RGC-specific gene therapy rescues neurodegeneration and visual function
Liu D
Molecular Therapy 2022; 30: 1421-1431
98807 CRISPR genome surgery in a novel humanized model for autosomal dominant retinitis pigmentosa
Hsu CW
Molecular Therapy 2022; 30: 1407-1420
98223 Endosomal disentanglement of a transducible artificial transcription factor targeting endothelin receptor A
Frauenknecht T
Molecular Therapy 2022; 30: 855-867
98807 CRISPR genome surgery in a novel humanized model for autosomal dominant retinitis pigmentosa
Cui X
Molecular Therapy 2022; 30: 1407-1420
98223 Endosomal disentanglement of a transducible artificial transcription factor targeting endothelin receptor A
Gerard MA
Molecular Therapy 2022; 30: 855-867
98727 NMNAT2 is downregulated in glaucomatous RGCs, and RGC-specific gene therapy rescues neurodegeneration and visual function
Huang H
Molecular Therapy 2022; 30: 1421-1431
98807 CRISPR genome surgery in a novel humanized model for autosomal dominant retinitis pigmentosa
Ryu J
Molecular Therapy 2022; 30: 1407-1420
98727 NMNAT2 is downregulated in glaucomatous RGCs, and RGC-specific gene therapy rescues neurodegeneration and visual function
Li L
Molecular Therapy 2022; 30: 1421-1431
98223 Endosomal disentanglement of a transducible artificial transcription factor targeting endothelin receptor A
Salat M
Molecular Therapy 2022; 30: 855-867
98807 CRISPR genome surgery in a novel humanized model for autosomal dominant retinitis pigmentosa
Quinn PMJ; Quinn PMJ
Molecular Therapy 2022; 30: 1407-1420
98727 NMNAT2 is downregulated in glaucomatous RGCs, and RGC-specific gene therapy rescues neurodegeneration and visual function
Chen W
Molecular Therapy 2022; 30: 1421-1431
98807 CRISPR genome surgery in a novel humanized model for autosomal dominant retinitis pigmentosa
Quinn PMJ
Molecular Therapy 2022; 30: 1407-1420
